{"id":"W2061718990","doi":"10.1182/blood-2008-08-175323","title":"Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; Takeda Oncology; National Institutes of Health; Otsuka Pharmaceutical; Astellas Pharma; Therakos; Kiadis Pharma; Association of Medical Microbiology and Infectious Disease Canada; American Society for Blood and Marrow Transplantation; Teva Pharmaceutical Industries; WellPoint; HistoGenetics; CellGenix; Medical College of Wisconsin; Enzon Pharmaceuticals; U.S. Navy; Centers for Disease Control and Prevention; Celgene; Osiris Therapeutics; Pfizer; Baxter International; Health Resources and Services Administration; Viropharma; Amgen; Blue Cross and Blue Shield Association; U.S. Department of Health and Human Services; Astellas Pharma US; Bayer HealthCare; U.S. Department of Defense","keywords":"Medicine; Filgrastim; Adverse effect; Nausea; Internal medicine; Surgery; Apheresis; Granulocyte colony-stimulating factor; Bone marrow; Odds ratio; Donation; Chemotherapy; Platelet","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00515355,0.00065132,0.0009857477,0.0003093182,0.0005007861,0.0007928152,0.0004315531,0.0006978941,0.001411489],"category_scores_gemma":[0.004037479,0.0002865354,0.00127079,0.0005423224,0.0007193177,0.0005318627,0.0004198662,0.001092354,0.0002442831],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000397254,"about_ca_system_score_gemma":0.0007536066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003738523,"about_ca_topic_score_gemma":0.0004685397,"domain_scores_codex":[0.9974069,0.001824603,0.0001872708,0.0002587283,0.0002260541,0.0000964437],"domain_scores_gemma":[0.9951521,0.002007627,0.001464033,0.0004014763,0.0002290233,0.0007456248],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5950853,0.02082008,0.2869698,0.001224728,0.00417531,0.0004827061,0.0004219132,0.0008808081,0.004243858,0.0001573068,0.001771964,0.08376629],"study_design_scores_gemma":[0.2811073,0.4724079,0.2324107,0.0001755523,0.004124183,0.001283117,0.0002240462,0.001439178,0.003895398,0.0003403692,0.002516173,0.00007597735],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967931,0.001769242,0.0002460324,0.00006087435,0.00002249975,0.0004051081,0.0003773546,0.000009666625,0.0003161997],"genre_scores_gemma":[0.9964246,0.001191286,0.0004538516,0.0002355636,0.00008659108,0.0005538437,0.0007584385,0.00000536545,0.0002903697],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00515355,"threshold_uncertainty_score":0.02725494,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0164950481682837,"score_gpt":0.2625234781842674,"score_spread":0.2460284300159837,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}